[July 15, 2014] |
|
Research and Markets: Esophageal Cancer Therapeutic Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/jlb58s/esophageal_cancer)
has announced the addition of the "Esophageal
Cancer - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Esophageal Cancer, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Esophageal Cancer and special features on late-stage and discontinued
projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic ladscape of
Esophageal Cancer
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Esophageal Cancer and enlists all their major and
minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Esophageal Cancer products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Esophageal Cancer pipeline on the basis of target,
MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Mentioned
-
Bristol-Myers Squibb Company
-
Boehringer Ingelheim GmbH
-
Amgen Inc.
-
GlaxoSmithKline plc
-
Gilead Sciences, Inc.
-
Daiichi Sankyo Company, Limited
-
Novartis AG
-
Ono Pharmaceutical Co., Ltd.
-
CTI (News - Alert) BioPharma Corp.
-
Genmab A/S
-
Advaxis, Inc.
-
Immunomedics, Inc.
-
Takara Bio Inc.
-
Synta Pharmaceuticals Corp.
-
Transgene Biotek Limited
-
Supratek Pharma Inc.
-
Glycotope GmbH
-
Hutchison MediPharma Limited
-
Advantagene, Inc.
-
CerRx, Inc.
-
Cerulean Pharma, Inc.
-
MacroGenics, Inc.
-
Merrimack Pharmaceuticals, Inc.
-
Omnitura Therapeutics Inc.
-
Omeros Corporation
-
Oncolys BioPharma Inc.
-
ImmunoFrontier, Inc.
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
-
Mebiopharm Co., Ltd.
-
Kite Pharma, Inc
For more information visit http://www.researchandmarkets.com/research/jlb58s/esophageal_cancer
[ Back To TMCnet.com's Homepage ]
|